Generic drug specialist Reception Contact Hospitals & Clinics area Officines area Accord Healthcare France SAS Accord Healthcare is a subsidiary of the Intas Pharmaceuticals LTD group created in 1976. The group has grown strongly on a global scale. It is now present in 55 countries and is positioned as a major player in the pharmaceutical industry. Accord Healthcare is actively involved in the marketing of pharmaceutical specialties in various therapeutic areas, in particular: • oncology • anesthesia • pathologies of the cardiovascular system • metabolic disorders We have developed a recognized expertise for a very wide range of formulations, from tablets to injectable forms and recently bio similar ones. We are committed to the quality of our products and to our perpetual desire for innovation. We are more than ever listening to healthcare professionals. Safety information This section mentions the precautions you should be aware of when using certain Accord Healthcare France medicines. VORICONAZOLE ACCORD 50mg & 200mg, film-coated tablet VORICONAZOLE ACCORD 200mg, powder for solution for infusion Information intended for hematologists, infectious disease specialists, Transplantation Centers and Resource and Competence Centers for Cystic Fibrosis (CRCM) When prescribing VORICONAZOLE ACCORD, special attention must be paid to the risks of phototoxicity , cutaneous squamous cell carcinomas (CEC) and of liver toxicity associated with the use of voriconazole. In order to communicate these key messages, and to inform patients of these risks, we provide you with the following documents: Questions / Answers brochure for your attention, containing important safety information and presenting the various documents available within the framework of this PRR for the monitoring and management of these risks; Questions / Answers brochure for prescribing physicians V1 07.2016 Follow-up assistance document (Checklist) for your attention, allowing you to remind you: § The measures to be taken to assess and deal with these risks, § inform the patient and / or the person providing care of these risks, in order to draw their attention to their clinical manifestations. This allows him to immediately seek medical advice in the event of the appearance of these clinical signs. Document d'aide au suivi (Check-list) à destination des médecins prescripteurs V1 07.2016 Carte Patient à remettre aux patients permettant de les alerter sur : § les mesures appropriées visant à réduire ces risques : éviter de s’exposer au soleil, utiliser des écrans solaires et des vêtements couvrants. § les signes et symptômes à vous rapporter. cette carte doit être portée par les patients dans leurs activités quotidiennes. Carte Patient à destination des patients V1 07.2016 ARIPIPRAZOLE ACCORD 5 mg, comprimé ARIPIPRAZOLE ACCORD 10 mg, comprimé ARIPIPRAZOLE ACCORD 15 mg, comprimé Information intended for medical specialists in psychiatry This Risk Minimization Plan (PMR) relates more specifically to the indication of aripiprazole (oral forms) for the treatment of moderate to severe manic episodes of type I bipolar disorder, in elderly adolescents 13 years of age or over, for up to 12 weeks. We provide you with the following documents: Physician brochure for your attention, containing important safety information and presenting the various documents available within the framework of this PRM Prescriber brochure Brochure Patient, destinée à vos patients et à leur entourage, résumant les principales informations que le patient doit connaître sur son traitement par aripiprazole Brochure patient Reporting of adverse reactions: Any laboratory marketing a drug must implement a pharmacovigilance system. The purpose of this is to collect and enable the scientific evaluation of undesirable effects, with the aim of prevention and reduction of risks and, if necessary, to take appropriate measures. Health professionals and manufacturers are required to report any adverse reactions of which they are aware, whether they are related to a drug, a medical device or any other health product. Declaration forms can be downloaded from the ANSM website: http://ansm.sante.fr/Declarer-un-effet-indesirable/Comment-declarer-un-effet-indesirable/Declarer-un-effet-indesirable -mode-d-emploi /% 28offset% 29/0 Date updated: 16-01-2017 Note: this website and its information are intended exclusively for French residents A subsidiary of the INTAS PHARMACEUTICALS LTD Group Création Idéloquence - Legal notice Sitemap Expressions for a Healthy Life